Janux Therapeutics, Inc.
JANX
$24.25
$0.984.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | 20.42% | 11.78% | |||
| Gross Profit | -20.42% | -14.48% | |||
| SG&A Expenses | 19.79% | -53.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.24% | -20.01% | |||
| Operating Income | -20.24% | 19.03% | |||
| Income Before Tax | -16.28% | 27.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.28% | 27.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.28% | 27.95% | |||
| EBIT | -20.24% | 19.03% | |||
| EBITDA | -20.58% | 19.31% | |||
| EPS Basic | -6.94% | 30.74% | |||
| Normalized Basic EPS | -6.97% | 30.75% | |||
| EPS Diluted | -6.94% | 30.74% | |||
| Normalized Diluted EPS | -6.97% | 30.75% | |||
| Average Basic Shares Outstanding | 8.73% | 4.03% | |||
| Average Diluted Shares Outstanding | 8.73% | 4.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||